Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 2957567 | https://doi.org/10.1155/2020/2957567

Peicheng Zhong, Lijun Song, Mengyue Gao, Xiaotong Wang, Wenpan Tan, Huanqian Lu, Qian Lan, Zuyi Zhao, Wenchang Zhao, "Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis", Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 2957567, 12 pages, 2020. https://doi.org/10.1155/2020/2957567

Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis

Academic Editor: Vincenzo De Feo
Received09 Apr 2020
Revised28 Jun 2020
Accepted13 Jul 2020
Published30 Jul 2020

Abstract

Ethnopharmacological Relevance. Gegen Qinlian decoction (GGQLD) is an effective formula treatment for rotavirus enteritis (RVE), which has been applied for 1900 years. It consists of 4 herbal medicines corresponding to the four roles “monarch, minister, assistant, and guide,” which is the basic rule of prescription composition in traditional Chinese medicine (TCM). However, its active ingredients and therapeutic mechanism on RVE have not been fully investigated. Materials and Methods. In this study, a network pharmacology-based strategy was used to elucidate the mechanism of GGQLD for the treatment of RVE. Oral bioavailability and drug-likeness were taken as the judgment criteria to search the active ingredients of GGQLD in traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). The affinity between protein and ingredients was further determined using the similarity ensemble approach to find the corresponding targets. According to the genes related to enteritis in GeneCards database, the key targets were screened by intersections between drug and disease targets. And the therapeutic mechanism was predicted using the protein-protein interactions (PPIs), the Gene Ontology (GO), and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, which was verified by detecting calcium ion concentration with the fluorescent probe. Result. 130 active ingredients were screened from GGQLD, including (R)-canadine, moupinamide, formononetin, and other flavonoids. They act on a total of 366 targets, which is mainly distributed in the biological process of hormone binding or signaling pathways of neuroactive ligand receptor interaction, serotonergic synapse, and calcium signaling pathway. Furthermore, serotonin receptors, adrenergic receptors, cholinergic receptors, and dopamine receptors in the enteric nervous system may be the key targets of RVE treatment by GGQLD. Conclusion. This study demonstrated that the potential mechanism that GGQLD can effectively improve the symptoms of RVE may depend on the regulation of calcium ions, serotonin, and gastrointestinal hormone ion that could mutually affect the intestinal nervous system.

1. Introduction

Traditional Chinese medicine (TCM), which has been widely used in clinical practice in China for thousands of years, takes multimedicinal materials compatibility for treating complex diseases [1]. And TCM formulas could be considered a complex system that consists of hundreds of chemical compounds, which exert synergistic, mutual assistance therapeutic action with fewer side effects on the complex giant system of the human body [2]. Thus, it presents a serious challenge to explain the mechanism of action of TCM formulas.

Network pharmacology is a systematic analytical method based on the interaction network of diseases, genes, protein targets, and drugs to elucidate the mechanism of drug action [3]. With the help of computational network pharmacology, it could explain TCM formulas’ acting characteristics of integrity, synergy, and dynamic in a holistic view and affords new sights into the multicomponent and multitargeted therapeutics of TCM. Therefore, network pharmacology holds a powerful and promising tool for analyzing TCM formulas.

GGQLD, a four-herb Chinese medicine formula first described 1900 years ago, is composed of Pueraria lobate, Scutellaria baicalensis, Coptis chinensis, and Glycyrrhiza uralensis. It has definite curative effect on RVE [4, 5], which is characterized by diarrhea, vomiting, fever, and so on. More than 200,000 infant deaths by RV are noted annually without specific drugs in clinic [6]. But the complex composition of GGQLD makes it difficult to conduct molecular mechanistic research on it in depth.

In this study, network pharmacology strategy was adopted to study the mechanism of GGQLD against RVE. The active ingredients of GGQLD and their targets intersected with disease genes were identified to investigate network relationships between drugs, targets, and diseases through network pharmacology (Figure 1).

2. Materials and Methods

2.1. Reagent and Materials

Caco-2 cells were from Wuhan university cell bank (Wuhan, China). RV-WA was from the immunology institute of the Third Military Medical University (Chongqing, China). Hoechst dye was purchased from Solarbio Company (Beijing, China). Fura-3 fluorescence was purchased from Beyotime Company (Shanghai, China). The Pueraria lobate, Scutellaria baicalensis, Coptis chinensis, and Glycyrrhiza uralensis were purchased from Dongguan Sinopharm Group (product batch number: 20190501, Dongguan, China). High glucose medium and fetal bovine serum were purchased from Gibco Company (USA).

2.2. Database Construction
2.2.1. Compound Database Construction

We obtained information of GGQLD active ingredients from the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) (http://sm.nwsuaf.edu.cn/lsp/tcmsp.php), which is a comprehensive TCM database for network pharmacology and also provides ideal information of the ADME (absorption, distribution, metabolism, and excretion) properties of natural compounds [7]. With TCMSP, the active ingredients of GGQLD were mainly filtered through the criteria of oral bioavailability (OB) and drug-likeness (DL), which are important indicators to evaluate ADME properties through bioinformatics. The increase in OB can achieve maximum efficacy and minimal side effects [8]. DL has been widely used to screen compounds with undesirable properties [9]. The QSAR models based on multiple linear regression (MLR), partial least squares regression (PLS), and nonlinear support-vector machine regression (SVR) have good potential to predict OB [10]. For DL, it is used in the drug design after evaluating whether it is similar to the physicochemical property and structural characteristics of existing drugs, which refers to molecular weight, one-dimensional descriptors, two-dimensional profiles, three-dimensional variables, and total positive and negative charges. In general, we calculate the DL by the Tanimoto coefficient, a formula based on database [11]: f(x,y)=xy/|x|2+|y|2xy (X represents the new numerator, and y represents the overall parameters of all ingredients in Drug-Bank database). In this study, active ingredients with OB index ≥30% and DL index ≥0.18 were selected as follow-up studies.

2.2.2. Active Ingredients Targeted Protein and Genes Database Construction

To obtain more detailed multicomponent drug targets, the next essential step was to find the specific targets where the drug ingredients play a pharmacodynamic role [12]. With the development of systems biology and computational methods, the ways to predict molecular targets are more abundant and reliable [13]. Here, we used a technique called similarity ensemble approach (http://sea.bkslab.org/) to obtain protein targeted by active ingredients from GGQLD, which is based on the chemical similarity among their ligands to match protein. Although the ligands are similar in the structure, both of them do not have an identical ligand [14]. Before searching the target protein limited to Homo sapiens in similarity ensemble approach, we had to get the canonical SMILES of the active ingredients as search term through PubChem platform (https://pubchem.ncbi.nlm.nih.gov/). Finally, we further used UniProtKB database (http://www.uniprot.org/) to verify the standard protein name and obtain the corresponding gene name as targets, which is the authority for the functional information of proteins [15].

2.2.3. RVE Disease Target Genes Database Construction

To maximize the total effective disease targets, we search them with the keyword “enteritis” in the database called GeneCards (https://www.genecards.org). From this database, we can obtain the relevant action enteritis-related genes of Homo sapiens, which included the all targets associated with RVE in particular.

2.3. TCM-Intersecting Targets-Disease Network Construction

The intersecting targets, displayed by Venn diagrams, were obtained between the targets of GGQLD ingredients and the RVE disease genes, which were used for the construction of PPI network and TCM-intersecting targets-disease network. First, based on the intersecting targets, PPI network was constructed to predict the interacting proteins through the STRING database (https://string-db.org/) with the multiple proteins function and the threshold of 0.95 interaction score. And the statistical interaction connectivity of proteins was used to determine the top 8 proteins. Next, in order to visualize the TCM-intersecting targets-disease network, we used Cytoscape software 3.7.1 to express the relationship between them in the form of a network diagram, where the nodes represented diseases, ingredients, or targets, and the lines represented nodes’ associations.

2.4. Biological Function Analysis

Through R language software (3.4.4) and Biocon-ductor’s biocLite.R, the above intersecting targets were performed to GO enrichment analysis (from the biological processes) and KEGG enrichment analysis. GO (http://geneontology.org/) is used to annotate the genes of different species from three independent ontologies including biological process, molecular function, and cellular component [16]. Furthermore, KEGG (http://www.genome.jp/kegg/) is a database that has access to specifically analyze the distribution of intersecting targets in the pathway [17]. Finally, was selected as the standard of significant enrichment to obtain the biological processes and signaling pathways in which GGQLD participated in the anti-RVE pharmacological role. The Cytoscape software 3.7.1 was used to visualize and analyze their related targets and active ingredients interaction network.

2.5. Functional Validation by Detection of Calcium Ions
2.5.1. Preparation of GGQLD and Cytotoxicity Test

15 g of Pueraria lobate, 9 g of Scutellaria baicalensis, 9 g of Coptis chinensis, and 6 g of Glycyrrhiza uralensis with 8 times weight of water were taken. Pueraria lobate was decocted for 20 min firstly, and the remaining herbs were decocted for a total of 30 min. Besides, the half-inhibitory concentration (IC50) of GGQLD to Caco-2 cells was measured by MTT colorimetry.

2.5.2. Cell Culture and GGQLD Treatment

Caco-2 cells were routinely cultured in high-sugar DMEM medium containing 10% fetal bovine serum (containing 1% antipenicillin and streptomycin). It was placed in an incubator at 37°C and 5% carbon dioxide. After it grew to a monolayer, it was routinely digested. Then, it was inoculated on the laser confocal special dish according to the density of 1 × 105 cells, which were divided into the control group, RV group, and GGQLD group. After 24 h of culture, the culture medium of the RV group and GGQLD group was removed. Then, 0.1 ml RV-WA with a virus titer of 10−4/0.1 ml (firstly incubated with 10 μg/ml trypsin for 30 min at 37°C) and 0.9 ml serum-free DMEM culture medium were added, while the control group was added 1 ml serum-free DMEM culture medium. After 2 h of infection, the culture medium of the control group and RV group was removed and 2 ml serum-free DMEM culture medium was added for 24 h. But the GGQLD group was added 2 ml serum-free DMEM culture medium with 4.8 mg/ml of GGQLD.

2.5.3. Determination of Intracellular Calcium Ion Intensity

Upon completion, changes in intracellular calcium ion intensity were measured using a laser confocal microscope (Leica SP8) and fura-3 fluorescence loading technology. The cells were incubated in serum-free DMEM culture solution containing 5 μM fluo-3/AM fluorescent probe at 37°C for 30 min. The incubation solution was removed and then added 1 ml 5 μg/ml Hoechst dye to be incubated for 5 min. Finally, the cells were washed twice with PBS buffer solution. Finally, the fluorescence intensity of calcium ions was measured with the laser confocal microscope at the excitation wavelength of 488 nm and the absorption wavelength of 515–565 nm.

3. Results

3.1. Composition Analysis

After searching, 142 active ingredients that passed the OB and DL filters were identified from the TCMSP database. However, only 130 of these ingredients showed the shared targets across disease genes (shown in Table 1), and the active ingredients with the number of intersecting targets >5 are listed in Table 2.


HerbsCompound nameOBDLPubChem ID

Pueraria lobateFormononetin69.670.215280378
3′-Methoxydaidzein48.570.245319422
Daidzein-4,7-diglucoside47.270.67171292

Scutellaria baicalensisAcacetin34.970.245280442
Wogonin30.680.235281703
(2R)-7-Hydroxy-5-methoxy-2-phenyl-2,3-dihydrochromen-4-one55.230.2821279
Baicalein33.520.215281605
5,8,2′-Trihydroxy-7-methoxyflavone37.010.27156992
5,7,3′,6′-Tetrahydroxy-6,8,2′-trimethoxyflavone33.820.4544258628
Carthamidin41.150.24188308
2,6,2′,4′-Tetrahydroxy-6′-methoxychalcone69.040.2278385588
Dihydrobaicalin_qt40.040.2114135323
Eriodyctiol41.350.24373261
Salvigenin49.070.33161271
5,2′,6′-Trihydroxy-7,8-dimethoxyflavone45.050.335322059
5,7,2′,6′-Tetrahydroxyflavone37.010.245321865
Dihydrooroxylin A38.720.23177032
Skullcapflavone II69.510.44124211
Oroxylin A41.370.235320315
Panicolin76.260.295320399
5,7,4′-Trihydroxy-8-methoxyflavone36.560.275322078
NEOBAICALEIN104.340.44124211
2β-Phenyl-2,3-dihydro-5,7-dihydroxy-6-methoxy-4H-1-benzopyran-4-one66.060.2325721350
β-Sitosterol36.910.75222284
3-Epi-β-sitosterol36.910.7512303645
Norwogonin39.40.215281674
5,2′-Dihydroxy-6,7,8-trimethoxyflavone31.710.35159029
Ent-Epicatechin48.960.24182232
Stigmasterol43.830.765280794
Coptisine30.670.8672322
Bis[(2S)-2-ethylhexyl]benzene-1,2-dicarboxylate43.590.357057920
Supraene33.550.42638072
Diop43.590.3933934
Epiberberine43.090.78160876
Moslosooflavone44.090.25188316
11,13-Eicosadienoic acid, methyl ester39.280.235365674
5,7,4′-Trihydroxy-6-methoxyflavanone36.630.275322074
5,7,4′-Trihydroxy-8-methoxyflavanone74.240.2642608119
Rivularin37.940.3713889022

Coptis chinensisBerberine36.860.782353
Obacunone43.290.77119041
Berberrubine35.740.7372703
(R)-Canadine55.370.77443422
Berlambine36.680.8211066
AC1O7GAS104.950.786604198
Magnograndiolide63.710.195319198
Palmidin A35.360.655320384
Palmatine64.60.6519009
Quercetin46.430.285280343
Worenine45.830.8720055073
Moupinamide86.710.265280537
Glycyrrhiza uralensisInermine75.180.5491510
DFV32.760.18114829
Mairin55.380.7864971
Glycyrol90.780.675320083
Jaranol50.830.295318869
Medicarpin49.220.34336327
Isorhamnetin49.60.315281654
3-Epi-β-sitosterol36.910.7512303645
Lupiwighteone51.640.375317480
7-Methoxy-2-methyl isoflavone42.560.2911486
Formononetin69.670.215280378
Calycosin47.750.245280448
Kaempferol41.880.245280863
Naringenin59.290.21932
Shinflavanone31.790.72197678
Glyasperin B65.220.44480784
Glyasperin F75.840.54392442
Glyasperin C45.560.4480859
Isotrifoliol31.940.425318679
(E)-1-(2,4-Dihydroxyphenyl)-3-(2,2-dimethylchromen-6-yl)prop-2-en-1-one39.620.3510881804
Kanzonol W50.480.5215380912
(2S)-6-(2,4-Dihydroxyphenyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro[3,2-g]chromen-7-one60.250.63637112
Semilicoisoflavone B48.780.555481948
Glepidotin A44.720.355281619
Glepidotin B64.460.34442411
Phaseolinisoflavan32.010.454484952
Glypallichalcone61.60.195317768
8-(6-Hydroxy-2-benzofuranyl)-2,2-dimethyl-5-chromenol58.440.3810542808
Licochalcone B76.760.195318999
Licochalcone G49.250.3249856081
Licoarylcoumarin59.620.4310090416
Licoricone63.580.475319013
Gancaonin A51.080.45317478
Gancaonin B48.790.455317479
Licorice glycoside E32.890.2742607811
Gancaonin L66.370.4114604077
Gancaonin M30.490.4114604078
Gancaonin O44.150.4114604081
Glycyrin52.610.47480787
Licocoumarone33.210.36503731
Licoisoflavone41.610.425281789
Licoisoflavone B38.930.555481234
Licoisoflavanone52.470.54392443
Shinpterocarpin80.30.7310336244
(E)-3-[3,4-Dihydroxy-5-(3-methylbut-2-enyl)phenyl]-1-(2,4-dihydroxyphenyl)prop-2-en-1-one46.270.3111267805
Liquiritin65.690.74503737
Licopyranocoumarin80.360.65122851
3,22-Dihydroxy-11-oxo-delta(12)-oleanene-27-alpha-methoxycarbonyl-29-oic acid34.320.55195396
Glyzaglabrin61.070.355317777
Glabridin53.250.47124052
Glabranin52.90.31124049
Glabrene46.270.44480774
Glabrone52.510.55317652
Hedysarimcoumestan B48.140.4311558452
3,5-Dihydroxy-13,14-dimethoxy-8,17-dioxatetracyclo[8.7.0.0(2),.0(1) (1),(1)]hepta-deca-1(10),2,4,6,11,13,15-hepta-en-9-one62.90.531160239
Eurycarpin A43.280.375317300
Glycyroside37.250.7944257223
(-)-Medicocarpin40.990.9523724664
Sigmoidin-B34.880.4173205
(2R)-7-Hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one71.120.18928837
Isobavachin36.570.32193679
Isoglycyrol44.70.84124050
Isolicoflavonol45.170.425318585
Isoformononetin38.370.213764
1-Methoxyphaseollidin69.980.64480873
Quercetin der46.450.3352761906
3′-Hydroxy-4′-O-methylglabridin43.710.5715228662
Licochalcone A40.790.295318998
3′-Methoxyglabridin46.160.5715228663
4′-Methoxyglabridin36.210.529927807
Icos-5-enoic acid30.70.23349565
Kanzonol F32.470.89101666840
6-Prenylated eriodictyol39.220.4113845972
7,2′,4′-Trihydroxy-5-methoxy-3-arylcoumarin83.710.2725015742
7-Acetoxy-2-methylisoflavone38.920.26268208
(2S)-3′,4′,5,7-Tetrahydroxy-8-prenylflavanone53.790.413845973
Gadelaidic acid30.70.25460988
Vestitol74.660.2192503
Gancaonin G60.440.39480780
Gancaonin H50.10.785481949
Licoagrocarpin58.810.5815840593
Glyasperin M72.670.59101664572
Glycyrrhiza flavonol A41.280.65317765
Licoagroisoflavone57.280.49636883
18-α-Hydroxyglycyrrhetic acid41.160.71101280181
Odoratin49.950.313965473
Phaseol78.770.5844257530
Xambioona54.850.8714769500
Dehydroglyasperin c53.820.37480775
Quercetin46.430.285280343


HerbsCompound namePubChem IDOBDL

Pueraria lobate3′-Methoxydaidzein531942248.570.24
Daidzein-4,7-diglucoside17129247.270.67
Acacetin528044234.970.24

Scutellaria baicalensisWogonin528170330.680.23
(2R)-7-Hydroxy-5-methoxy-2-phenyl-2,3-dihydrochromen-4-one82127955.230.2
Baicalein528160533.520.21
5,8,2′-Trihydroxy-7-methoxyflavone15699237.010.27
2,6,2′,4′-Tetrahydroxy-6′-methoxychalcone7838558869.040.22
β-Sitosterol22228436.910.75
Bis[(2S)-2-ethylhexyl]benzene-1,2-dicarboxylate705792043.590.35
Supraene63807233.550.42
Diop3393443.590.39
11,13-Eicosadienoic acid methyl ester536567439.280.23
(R)-Canadine44342255.370.77

Coptis chinensisQuercetin528034346.430.28
Moupinamide528053786.710.26
Mairin91148655.380.78
Formononetin528037869.670.21

Glycyrrhiza uralensisGlypallichalcone531776861.60.19
Icos-5-enoic acid334956530.70.2
7-Acetoxy-2-methylisoflavone26820838.920.26
Gadelaidic acid546098830.70.2

3.2. TCM-Intersecting Targets-Disease Network Analysis

Finally, we found 7149 enteritis-related targets and 552 GGQLD active ingredient targets, with 366 intersections (Figure 2(a)). The 366 intersecting targets were imported into the String database to obtain the PPI network targeting anti-RVE (Figure 2(b)). In this network, as shown in Figure 2(c), the top 8 genes with the highest node connectivity were EP300, AKT1, HSP90AA1, CTNNB1, EGFR, CDK1, HRAS, and KAT2B. Among them, EP300 has 31 connections with other genes, and 7 other genes have more than 15 connectivities. Finally, with the intersection genes as a hub, we constructed a network diagram of GGQLD-intersecting targets-active ingredients (represented by PubChem ID) RVE, which could clearly determine the relationship between them (Figure 2(d)).

3.3. Biological Functional Analysis

In terms of biological processes, the intersecting targets demonstrate multiple functions (Figure 3(a)). The redder the color in the figure, the smaller the value, and the stronger the representativeness. The most interesting one is hormone binding with ID 0042562. The function is interpreted as selectively and noncovalently interacting with any of the hormones to influence the metabolism or behavior of other cells with hormone-functional receptors.

In the signal pathway, its importance evaluation criteria were similar to the GO diagram (Figure 3(b)). The results showed the following pathways with reference value: neuroactive ligand-receptor interaction with ID hsa04080, serotonergic synapse with ID hsa04726, calcium signaling pathway with ID hsa04020, and so on. These pathways were concentrated in the related expression of neural active substances, especially in the serotonergic system.

3.4. Active Ingredients-Interaction Targets-Pathways Network Analysis

Through Cytoscape software 3.7.1, the active ingredients and interaction targets related to the biological process horizon binding and the neuroactive ligand receptor interaction, serotonergic synapse, and calcium signaling pathway were visualized as the network (Figure 4). Among them, the active ingredients (R)-canadine, moupinamide, and formononetin, respectively, targeted 17, 17, and 11 targets. It is speculated that these active ingredients may be the key ingredients for GGQLD to exert anti-RVE effects through the above functional pathways. In addition, the serotonin receptor subfamily (HTR1A, HTR2B, and HTR7), the adrenergic receptor subfamily (ADRA2A, ADRA2B, ADRB1, ADRB2, and ADRB3), the cholinergic receptor subfamily (CHRM1, CHRM2, and CHRM3), and the dopamine receptor subfamily (DRD1, DRD2, DRD3, DRD4, and DRD5), respectively, corresponded to 8, 7, 7, and 7 active ingredients. It is speculated that these targets may be the key parts for GGQLD to exert anti-RVE efficacy through the above functional pathways.

3.5. GGQLD Inhibited the Release of Calcium Ions in Caco-2 Cells after RV Infection

After applying 4.8 mg/ml of GGQLD (IC50: 16.21 mg/ml, as shown in Figure 5(a)) to RV infected Caco-2 cells 24 hours, we observe the result with laser confocal microscope. As shown in Figure 5(b), intracellular calcium ion fluorescence intensity in Caco-2 cells infected with the RV was significantly stronger than the control group. However, the GGQLD group could reduce the fluorescence intensity of intracellular calcium ions in RV-infected Caco-2 cells, which showed that GGQLD had access to decrease the release of intracellular calcium ions.

4. Discussion

4.1. Analysis of Active Ingredients of GGQLD

From the TCMSP database, 130 active ingredients of GGQLD were found to be related to RVE, which mainly included the types of flavonoids, alkaloids, phenyl ester, and fatty acids. The flavonoids have the abilities to destroy the integrity of RV structure and protein synthesis, which has the potentials of anti-RV drug research [18, 19]. An ingredient called licocoumarone, for example, has the ability to suppress viral RNA synthesis in TF-104 cells [20]. From Figure 4, we also found that flavonoids such as formononetin, acacetin, wogonin, and quercetin were distributed in key pathways and target multiple disease genes. In addition, other active ingredients named (R)-canadine, icos-5-enoic-acid, moupinamide, and bis[(2S)-2-ethylhexyl]-benzene-1,2-dicarboxylate also had potential research value. Overall, we could find that Scutellaria baicalensis was the most influential Chinese medicine, containing a variety of key active ingredients.

4.2. Closely Related Target Analysis from the PPI Network

The PPI network showed that the deeper potential targets of GGQLD were related to proliferation and transcription. As the histone acetyltransferase, EP300 and KAT2B play a causative role in regulating transcription through internal lysine acetylation of multiple proteins and a rapid and reversible regulatory mechanism [21]. In addition, HSP90AA1, respectively, promotes autophagy and inhibits apoptosis through the PI3K/Akt/mTOR pathway and JNK/P38 pathway [22]. AKT1 (a downstream target of phosphatidylinositol 3-kinase) and CTNNB1 (a central part in Wnt/beta-catenin pathway) both have access to regulate a number of cellular proliferation and differentiation [23, 24]. And with the active autophosphorylation of receptor tyrosine kinase, EGFR could initiate a cascade of downstream signaling pathways involved in regulating cellular differentiation [25]. As for CDK1, it is required for the transition from the G2 phase into mitosis, which affects cell proliferation a lot [26]. In short, these targets with high connectivity are closely related to cell proliferation and differentiation.

4.3. The Impact of Hormone Binding

Gastrointestinal hormones are the basic regulators of intestinal absorption, metabolism, and homeostasis and play important roles in intestinal fitness [27]. Similar to GGQLD for damp-heat syndrome of TCM, ZHIXIE decoction may improve the efficacy of damp-heat RV infection enteritis by regulating gastrointestinal hormones [28]. In a variety of gastrointestinal hormones, vasoactive intestinal peptide in gastrointestinal hormones is associated with the pathways described below. In general, vasoactive intestinal peptide is synthesized under the activation of serotonin receptors on intrinsic primary afferent nerves that compose the myenteric plexus [29], which can cause diarrhea through up-regulated cAMP [30]. Interestingly, as shown in Figure 6, recent studies have reported that serotonin homeostasis can be destroyed by RV infection [31, 32].

4.4. The Analysis of Neuroactive Ligand-Receptor Interaction, Serotonergic Synapse, and Calcium Signaling Pathway

From the perspective of disease, RVE seems to be related to the intestinal nervous system [33]. For example, the enteric neurons have a lot to do with gastrointestinal functions and age, which are also related to RV [34]. And as described in the hormone binding analysis, recent studies have demonstrated that RVE has potential mechanisms that enteric nervous system was affected by serotonin, which was corresponding to the results of neuroactive ligand-receptor interaction and serotonergic synapse obtained by analysis [32]. Furthermore, it also shown that increased intracellular calcium level mediated by NSP4 could induce the serotonin of enterochromaffin cells, which can stimulate the intestinal nervous system and ultimately enhance the irritable bowel movement [31, 35, 36]. Besides, we found that RV infection in infants and young children would disrupt calcium homeostasis to increased calcium ion concentration in intestinal epithelial cells, which was closely related to infection [37]. It was corresponding to the results of calcium ion signaling pathway, which indicated that GGQLD may act on the calcium ion channel to achieve therapeutic effect. In terms of experimental results, this study also preliminarily found that GGQLD could inhibit the condition that RV increased calcium release in Caco-2 cells. In short, we supposed GGQLD mainly achieves antidiarrhea effects on the calcium ion release, serotonin homeostasis, gastrointestinal hormones, and intestinal nerve system (Figure 6).

5. Conclusions

GGQLD had 130 active ingredients in the treatment of RVE, such as (R)-canadine, formononetin, and moupinamide. They targeted 366 genes to regulate the secretion of gastrointestinal hormones of intestinal epithelial cells and stabilize the secretion of calcium ions and serotonin, among which serotonin receptors, adrenergic receptors, cholinergic receptors, and dopamine receptors were potential key points. In summary, this study reveals the anti-RVE mechanism of GGQLD through multicomponent-multitarget-multipathway and provided new ideas for comprehensive and in-depth clarification of the mechanism of GGQLD in the treatment of RVE.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

Peicheng Zhong and Lijun Song are the co-first authors.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Peicheng Zhong, Lijun Song, and Mengyue Gao were responsible for the research concept, design, and literature retrieval. Peicheng Zhong, Zuli Zhao, and Xiaotong Wang were responsible for data analysis and interpretation. Wenpan Tan and Huanqian Lu drafted the paper. Qian Lan and Wenchang Zhao have made extensive modifications. All authors participated in the analysis and interpretation of the data and passed the final paper. Peicheng Zhong and Lijun Song made equal contributions to this work.

Acknowledgments

This study was funded by the National Natural Science Foundation of China (nos. 81973548 and 81473401) and Key Project of Social Science and Technology Development of Dongguan (no. 20185071521658).

References

  1. C. Li, Q. Li, R. Liu et al., “Medicinal herbs in the prevention and treatment of osteoporosis,” The American Journal of Chinese Medicine, vol. 42, no. 1, pp. 1–22, 2014. View at: Publisher Site | Google Scholar
  2. F. Tang, Q. Tang, Y. Tian, Q. Fan, Y. Huang, and X. Tan, “Network pharmacology-based prediction of the active ingredients and potential targets of Mahuang Fuzi Xixin decoction for application to allergic rhinitis,” Journal of Ethnopharmacology, vol. 176, pp. 402–412, 2015. View at: Publisher Site | Google Scholar
  3. A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008. View at: Publisher Site | Google Scholar
  4. L. Song, W. Zhao, X. Tan, M. Yang, and J. Luo, “Effect of Gegen Qinlian decoction on rotavirus-inducing diarrhea in neonatal mice,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 20, no. 7, pp. 35–37, 2013. View at: Google Scholar
  5. J. Shen, J. Chen, Y. Chen, and L. Zhao, “Clinical observation on 20 cases of rotavirus diarrhea treated with Gegen Qinlian decoction,” Chinese Medicine Modern Distance Education of China, vol. 11, no. 2, pp. 91–93, 2013. View at: Google Scholar
  6. S. E. Crawford, S. Ramani, J. E. Tate et al., “Rotavirus infection,” Nature Reviews Disease Primers, vol. 3, p. 17083, 2017. View at: Publisher Site | Google Scholar
  7. J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014. View at: Publisher Site | Google Scholar
  8. R. Wang, D. P. Conner, and B. V. Li, “Bioavailability and bioequivalence aspects of oral modified-release drug products,” The AAPS Journal, vol. 19, no. 2, pp. 360–366, 2017. View at: Publisher Site | Google Scholar
  9. S. Tian, J. Wang, Y. Li, D. Li, L. Xu, and T. Hou, “The application of in silico drug-likeness predictions in pharmaceutical research,” Advanced Drug Delivery Reviews, vol. 86, pp. 2–10, 2015. View at: Publisher Site | Google Scholar
  10. X. Xu, W. Zhang, C. Huang et al., “A novel chemometric method for the prediction of human oral bioavailability,” International Journal of Molecular Sciences, vol. 13, no. 6, pp. 6964–6982, 2012. View at: Publisher Site | Google Scholar
  11. L. Liu, B. Du, H. Zhang et al., “A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome,” Chinese Medicine, vol. 13, no. 1, p. 46, 2018. View at: Publisher Site | Google Scholar
  12. M. Schenone, V. Dančík, B. K. Wagner, and P. A. Clemons, “Target identification and mechanism of action in chemical biology and drug discovery,” Nature Chemical Biology, vol. 9, no. 4, pp. 232–240, 2013. View at: Publisher Site | Google Scholar
  13. J. S. Fang, A. L. Liu, and G. H. Du, “Research advance in the drug target prediction based on chemoinformatics,” Yao Xue Xue Bao, vol. 49, no. 10, pp. 1357–1364, 2014. View at: Google Scholar
  14. M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. Shoichet, “Relating protein pharmacology by ligand chemistry,” Nature Biotechnology, vol. 25, no. 2, pp. 197–206, 2007. View at: Publisher Site | Google Scholar
  15. C. T. UniProt, “UniProt: the universal protein knowledgebase,” Nucleic Acids Research, vol. 46, no. 5, p. 2699, 2018. View at: Google Scholar
  16. M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene Ontology: tool for the unification of biology,” Nature Genetics, vol. 25, no. 1, pp. 25–29, 2000. View at: Publisher Site | Google Scholar
  17. M. Tanabe and M. Kanehisa, “Using the KEGG database resource,” Current Protocols in Bioinformatics, vol. 11, no. 1, 2012. View at: Google Scholar
  18. G. R. Gandhi, P. G. Barreto, B. d. S. Lima et al., “Medicinal plants and natural molecules with in vitro and in vivo activity against rotavirus: a systematic review,” Phytomedicine, vol. 23, no. 14, pp. 1830–1842, 2016. View at: Publisher Site | Google Scholar
  19. H. Huang, D. Liao, L. Liang, L. Song, and W. Zhao, “Genistein inhibits rotavirus replication and upregulates AQP4 expression in rotavirus-infected Caco-2 cells,” Archives of Virology, vol. 160, no. 6, pp. 1421–1433, 2015. View at: Publisher Site | Google Scholar
  20. H.-J. Kwon, H.-H. Kim, Y. B. Ryu et al., “In vitro anti-rotavirus activity of polyphenol compounds isolated from the roots of Glycyrrhiza uralensis,” Bioorganic & Medicinal Chemistry, vol. 18, no. 21, pp. 7668–7674, 2010. View at: Publisher Site | Google Scholar
  21. M.-H. Kuo and C. D. Allis, “Roles of histone acetyltransferases and deacetylases in gene regulation,” Bioessays, vol. 20, no. 8, pp. 615–626, 1998. View at: Google Scholar
  22. X. Xiao, W. Wang, Y. Li et al., “HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma,” Journal of Experimental & Clinical Cancer Research, vol. 37, no. 1, p. 201, 2018. View at: Publisher Site | Google Scholar
  23. S. Boyault, D. S. Rickman, A. de Reyniès et al., “Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets,” Hepatology, vol. 45, no. 1, pp. 42–52, 2007. View at: Publisher Site | Google Scholar
  24. R. T. Moon, “Wnt/beta-catenin pathway,” Science Signaling, vol. 2005, no. 271, 2005. View at: Publisher Site | Google Scholar
  25. D. Singh, B. Kumar Attri, R. Kaur Gill, and J. Bariwal, “Review on EGFR inhibitors: critical updates,” Mini-Reviews in Medicinal Chemistry, vol. 16, no. 14, pp. 1134–1166, 2016. View at: Publisher Site | Google Scholar
  26. M. Malumbres, “Cyclin-dependent kinases,” Genome Biology, vol. 15, no. 6, p. 122, 2014. View at: Publisher Site | Google Scholar
  27. M. Wabitsch, “Gastrointestinal hormones induced the birth of endocrinology,” Developmental Biology of Gastrointestinal Hormones, vol. 32, pp. 1–7, 2017. View at: Publisher Site | Google Scholar
  28. M. Li, Y. Wang, N. Luo, and J. Cui, “Effect of Chinese herbal Zhixie Decoction on immune function and Gastrointestinal hormones in patients with damp-heat rotavirus infection,” Northwest Pharmaceutical Journa, vol. 34, no. 2, pp. 241–244, 2019. View at: Google Scholar
  29. M. Hagbom, C. Istrate, D. Engblom et al., “Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and activates brain structures involved in nausea and vomiting,” PLoS Pathogens, vol. 7, no. 7, 2011. View at: Publisher Site | Google Scholar
  30. C. D. Rao, P. P. Maiya, and M. A. Babu, “Non-diarrhoeal increased frequency of bowel movements (IFoBM-ND): enterovirus association with the symptoms in children,” BMJ Open Gastroenterology, vol. 1, no. 1, 2014. View at: Publisher Site | Google Scholar
  31. S. Bialowas, M. Hagbom, J. Nordgren et al., “Rotavirus and serotonin cross-talk in diarrhoea,” PLoS One, vol. 11, no. 7, 2016. View at: Publisher Site | Google Scholar
  32. S. Kordasti, H. Sjovall, O. Lundgren, and L. Svensson, “Serotonin and vasoactive intestinal peptide antagonists attenuate rotavirus diarrhoea,” Gut, vol. 53, no. 7, pp. 952–957, 2004. View at: Publisher Site | Google Scholar
  33. A. P. Morris and M. K. Estes, “VIII. Pathological consequences of rotavirus infection and its enterotoxin,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 281, no. 2, pp. G303–G310, 2001. View at: Publisher Site | Google Scholar
  34. M. J. Saffrey, “Cellular changes in the enteric nervous system during ageing,” Developmental Biology, vol. 382, no. 1, pp. 344–355, 2013. View at: Publisher Site | Google Scholar
  35. A. L. Chang-Graham, J. L. Perry, A. C. Strtak et al., “Rotavirus calcium dysregulation manifests as dynamic calcium signaling in the cytoplasm and endoplasmic reticulum,” Scientific Reports, vol. 9, no. 1, p. 10822, 2019. View at: Publisher Site | Google Scholar
  36. T. Pham, J. L. Perry, T. L. Dosey, A. H. Delcour, and J. M. Hyser, “The rotavirus NSP4 viroporin domain is a calcium-conducting ion channel,” Scientific Reports, vol. 7, Article ID 43487, 2017. View at: Publisher Site | Google Scholar
  37. J. M. Hyser, M. R. Collinson-Pautz, B. Utama, and M. K. Estes, “Rotavirus disrupts calcium homeostasis by NSP4 viroporin activity,” mBio, vol. 1, no. 5, 2010. View at: Publisher Site | Google Scholar

Copyright © 2020 Peicheng Zhong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views201
Downloads305
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.